Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.

摘要: Background : Ursodeoxycholic acid has been shown to be a useful agent in the clinical management of patients with primary biliary cirrhosis and autoimmune chronic active hepatitis. Its efficacy is presumed based upon its ability act as detergent incite choleresis. Recent additional data suggest it also reduces HLA antigen expression on liver epithelial cells impairs T cell reactivity. Methods A randomized controlled study 59 sclerosing cholangitis was performed over 24 months period 3 groups being studied. Group I consisted 20 who were given ursodeoxycholic 300 mg orally twice day ; group II 19 colchicine 0.6 BID III an untreated medical control group. All three seen at regular 3-month intervals had quarterly, annual terminal studies assess their disease status. Results No difference between evident after two full years therapy when parameters injury, function, size hepatic copper content compared groups. Similarly, no ERCP findings either entry or therapy. Conclusions These that better than simple follow-up. Thus, neither can considered effective therapies for cholangitis.